PMID: 789Nov 1, 1975

Allogeneic marrow transplantation for the treatment of leukaemia. A review

Scandinavian Journal of Haematology
T A AlvegårdR G Graw


22 HL-A antigen and mixed leukocyte culture-matched sibling bone marrow transplants were attempted in patients with acute leukaemia (at the National Cancer Institute) to define the toxicities of four different immunosuppressive regimens, the complications associated with warrow engraftment and antileukaemic effect. 73% (16/22) were engrafted as indicated by a change to donor red blood cells (RBC) type, leukocyte, immunoglobulin allotype or by the speed of morrow repopulation and the occurrence of the Graft Versus Host Disease (GVHD). 12 of 16 (75%) successful engrafted patients developed GVHD. The current published results of clinical bone marrow transplantation from major centers has been reviewed and will be discussed in relationship to current clinical complications associated with bone marrow transplantation.


Apr 17, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Apr 10, 1975·The New England Journal of Medicine·D J HigbyJ F Holland
Feb 5, 1972·Lancet·E D ThomasK G Lerner
Apr 4, 1970·Lancet·J J van Rood, V P Eijsvoogel
Jan 1, 1973·Transplantation·R StorbE D Thomas
Dec 1, 1972·Transplantation·R H HaltermanB G Leventhal
Aug 24, 1972·The New England Journal of Medicine·R G GrawE S Henderson
Jun 1, 1970·Transplantation·M M Bortin
Apr 1, 1971·Transplantation·A H Owens, G W Santos
Sep 12, 1957·The New England Journal of Medicine·E D THOMASJ W FERREBEE

Related Concepts

Bone Marrow Cells
Graft Vs Host Reaction
HLA Typing
HLA Antigens
Therapeutic Immunosuppression
Lymphoid Leukemia
Acute Monocytic Leukemia
Lymphocyte Culture Test, Mixed

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.